Jump to content

  • Set Your Location
  • Sign in or Enroll
Set Your LocationPalo Alto Medical Foundation
  • Sign in or Enroll
    • Open I want to choose my medical group or hospital
    • Clear my location
Change Location
Sutter Health
  • Video Visits
  • Find Doctors
  • Find Locations
  • Treatments & Services
    • Video Visits
    • Find Doctors
    • Find Locations
    • Treatments & Services
    • COVID-19 Resources
    • Pay a Bill
    • Symptom Checker
    • Get Care Today
    • Health & Wellness
    • Classes & Events
    • Research & Clinical Trials
    • For Patients
    • About Sutter Health
    • Giving
    • Volunteering
    • Careers
    • News
    • For Medical Professionals
    • Other Business Services
Close Search
  • Home
  • PAMF
  • Research
  • Cancer
Content

Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance.

Description

Chan JK, Liang SY, Kapp DS, Chan JE, Herzog TJ, Coleman RL, Monk BJ, Richardson MT., Gynecol Oncol. S0090-8258(20)33910-X. doi: 10.1016/j.ygyno.2020.09.017. Online ahead of print., 2020 Sep 26

Investigators

Su-Ying Liang, Ph.D., Research Economist / Faculty

Abstract

We have evaluated three clinical decision points with biomarker guidance that must be made in the upfront treatment of ovarian cancer. Our discussion provides a clinical pathway to guide clinicians on the selection of new upfront regimens for ovarian cancer incorporating bevacizumab and/or poly-adenosine diphosphate-ribose polymerase (PARP) inhibitors.

It is also important to recognize that the selection of upfront agents may influence treatment options at recurrence. For example, the addition of these novel agents may have marginal median progression-free survival (mPFS) benefit of only 3–6months; however, this clinical benefit may extend mPFS and categorize patients as “platinum-sensitive,” allow them to be eligible for the re-treatment of platinum combinations, or become eligible for more clinical trials.

Since clinicians have access to three PARPi (olaparib, niraparib, and rucaparib) in the platinum sensitive setting, they may choose to alternate the sequential use of these biologic agents from bevacizumab to PARPi or vice-versa depending on the initial response to these agents. Genetic and genomic testing serve as an important tool to triage patients towards maintenance therapy with biologic agents.

Further decision tree analysis with economic considerations are also warranted to evaluate sequential therapies beyond the upfront setting to reflect the overall ovarian cancer patient's treatment journey.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

  • Cancer
  • Disease Management
  • Genetics
  • Ovarian Cancer
  • Women's Health

Related Publications

Early diffusion of gene expression profiling in breast cancer patients associated with areas of high income inequality.

Ponce NA, Ko M, Liang SY, Armstrong J, Toscano M, Chanfreau-Coffinier C, Haas JS.
Health Aff (Millwood). 2015 Apr 1;34(4):609-15. doi: 10.1377/hlthaff.2014.1013.
2015 Apr 01

Linking electronic health records to better understand breast cancer patient pathways within and between two health systems.

Thompson CA, Kurian AW, Luft HS.
eGEMs (Generating Evidence & Methods to improve patient outcomes). 3(1).
2015 Mar 01

A randomized controlled effectiveness trial for PSA screening decision support interventions in two primary care settings.

Lewis CL, Adams J, Tai-Seale M, Huang Q, Knowles SB, Nielsen ME, Pignone MP, Walter LC, Frosch DL.
J Gen Intern Med. 2015 Jun;30(6):810-6. doi: 10.1007/s11606-015-3214-9. Epub 2015 Feb 10.
2015 Feb 10

Utilization of cardiac monitoring tests in women with non-metastatic breast cancer treated with trastuzumab.

Shin J, Liang SY, Hassett MJ, Phillips KA, Haas JS.
Personalized Medicine. 10(7): 703-708.
2013 Jan 01

Redefining risk and benefit: understanding the decision to undergo contralateral prophylactic mastectomy.

Rendle KA, Halley MC, May SG, Frosch DL.
Qual Health Res. pii: 1049732314557085. [Epub ahead of print]
2014 Nov 04
The Sutter Health Network of Care
Expertise to fit your needs
Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.

  • Contact Us
  • Find Doctors
  • Find Locations
  • Request Medical Records
  • Make a Gift
Sign in to My Health Online

Billing and Insurance

  • Pay a Bill
  • Accepted Health Plans
  • Estimate Costs
  • Medicare Advantage

About Sutter

  • About Our Network
  • Community Benefit
  • Annual Report
  • News

Our Team

  • For Employees
  • For Medical Professionals
  • For Vendors
  • For Volunteers

Careers

  • Jobs at Sutter
  • Physician Jobs
  • Graduate Medical Education

Copyright © 2023 Sutter Health. All rights reserved. Sutter Health is a registered trademark of Sutter Health ®, Reg. U.S. Patent & Trademark office.

  • ADA Accessibility
  • Privacy
  • Do Not Sell My Personal Information
  • LinkedIn Opens new window
  • YouTube Opens new window
  • Facebook Opens new window
  • Twitter Opens new window
  • Instagram Opens new window
  • Glassdoor Opens new window

Cookie Policy

We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences

Privacy Policy Cookie Preferences